CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for NovaDel Pharma, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

NovaDel Pharma, Inc.
1200 US Highway 22
Suite 2000
Phone: (908) 203-4640p:908 203-4640 Bridgewater, NJ  08807-2943  United States Ticker: NVD NVD
This company was Merged or Acquired on 8/14/2013.
This company ceased filing statements with the SEC on 3/30/2012.
On 2/22/2017, Novadel Pharma Inc. announced its shareholders had elected to dissolve the Company. It is expected that the dissolution and distribution to shareholders will be completed by 6/30/2017.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
NovaDel Pharma Inc. is a specialty pharmaceutical company developing oral spray formulations for a range of marketed pharmaceuticals. The Company’s oral spray technology is focused on addressing unmet medical needs for an array of existing and future pharmaceutical products. Its most advanced oral spray candidates target angina, insomnia, erectile dysfunction, migraine headaches, nausea and disorders of the central nervous system. The Company plans to develop these and other products independently and through collaborative arrangements with pharmaceutical and biotechnology companies. In August 2013, Suda Ltd announced that the acquisition of the NovaDel Pharma Inc. assets was completed.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201212/31/2010YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Steven B.Ratoff 73 6/16/2010 1/17/2006
Chief Financial Officer, Senior Vice President, Secretary Craig A.Johnson 54 6/16/2010 6/16/2010

Business Names
Business Name
FLEMW
Novadel Pharma Inc
Novadel Pharma, Inc.
NVD
NVDL

General Information
Number of Employees: 4 (As of 3/1/2011)
Outstanding Shares: 134,890,615 (As of 12/31/2011)
Shareholders: 62
Stock Exchange: OTC
Federal Tax Id: 222407152
Fax Number: (302) 636-5454


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023